Gene therapy research for Duchenne muscular dystrophy (DMD) continues to advance. At the MDA Clinical & Scientific Conference in Orlando, the French gene therapy organization Genethon presented new long-term data showing that its investigational therapy GNT0004 maintains clinical benefits two years after treatment.
The findings highlight improvements in motor function, reductions in muscle damage biomarkers, and a favorable safety profile in boys with Duchenne muscular dystrophy who received the therapy during the first phase of the clinical trial.
Table of Contents
Two-Year Results from the GNT0004 Clinical Trial
The international multicenter study enrolled ambulatory boys aged 6 to 10 years diagnosed with Duchenne muscular dystrophy.
During the dose-escalation phase, five patients received the therapy:
- Four patients in France
- One patient in the United Kingdom
Three patients received the therapeutic dose of 3×10¹³ vg/kg, and their long-term follow-up data form the basis of the new analysis.
After two years, the study showed:
- Sustained improvements in motor function
- Reduced muscle damage biomarkers
- Slower disease progression
- No serious safety concerns
Significant Improvement in NSAA Motor Function Scores
Motor function was evaluated using the North Star Ambulatory Assessment (NSAA), a widely used clinical scale for ambulatory DMD patients. Learn More: North Star Ambulatory Assessment (NSAA) in Duchenne
Key findings include:
- +9 point improvement in NSAA score at two years
- Compared with untreated patients matched through propensity score analysis
- Well above the 2.5-point threshold considered clinically meaningful
These results suggest that GNT0004 may significantly improve or stabilize motor abilities in treated patients.
Improvements in Walking Tests
Patients treated with GNT0004 also showed measurable gains in timed walking assessments:
- +173 meters difference in the 6-Minute Walk Test compared with untreated patients
- +0.95 m/s increase in the 10-Meter Walk Test speed
These functional improvements indicate that treated children maintained better mobility over time.
Large Reduction in Creatine Kinase (CK) Levels
Researchers also reported a major decline in Creatine Kinase (CK) levels, an important biomarker of muscle damage. Read More: What is Creatine Kinase (CK)?
Results showed:
- Average CK reduction of about 70% at two years
- Compared with each patient’s baseline before treatment
One patient followed for three years maintained stable CK levels, suggesting the therapy may have a long-lasting effect on muscle cell membrane stability.
MRI Imaging Shows Slower Disease Progression
Quantitative MRI imaging revealed slower muscle degeneration in treated patients.
Researchers observed:
- More than 18% difference in muscle fat fraction
- Compared with untreated patients in natural history cohorts
In Duchenne muscular dystrophy, higher fat infiltration typically reflects disease progression. Lower levels indicate preserved muscle tissue.
Favorable Safety Profile
The study reported no serious adverse events, confirming that the therapy was well tolerated.
Patients received temporary preventive immunosuppression, which helped minimize immune reactions to the gene therapy vector.
Pivotal Phase of the Research Now Underway
The ongoing pivotal phase of the clinical trial has been authorized by:
- European Medicines Agency (EMA)
- Medicines and Healthcare products Regulatory Agency (MHRA)
This phase will:
- Enroll 64 ambulatory boys aged 6–10 years
- Use a randomized, double-blind, placebo-controlled design
- Test the selected dose of 3×10¹³ vg/kg
Notably, this dose is lower than doses used in some other Duchenne gene therapy trials, which may offer safety advantages.
Find out more: Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
Why These Results Matter
Duchenne muscular dystrophy is a severe genetic disorder caused by mutations in the dystrophin gene. The disease leads to progressive muscle degeneration and loss of mobility.
Gene therapies like GNT0004 aim to deliver functional genetic material to muscle cells, potentially addressing the root cause of the disease.
The two-year results suggest that GNT0004 may:
- Improve motor function
- Reduce muscle damage
- Slow disease progression
- Maintain a manageable safety profile
Further results from the pivotal study will determine whether the therapy could eventually become an approved treatment option.
Follow This Page >>> All Clinical Trials for Duchenne
